Newsbenzinga
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
· Published
Article summary
Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.
An excerpt from the original article.
Comments —
Loading comments…